Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IAM1363 · 1 trial · 13 indications
Incidence and severity of DLTs during the first cycle of treatment in participants in Part 1
Incidence of treatment emergent AEs (TEAEs) and serious adverse events (SAEs)
PK parameters. Includes but is not limited to assessment of maximum concentration (Cmax).
Percentage of participants who achieve a confirmed objective response (complete response \[CR\] + partial response \[PR\]) per the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Percentage of participants who achieve a confirmed CNS-cORR (CNS-CR + CNS-PR) per the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) Criteria
As measured using standard ECG parameters, including pulse rate, QT intervals, and QRS duration.
| Arm | Type | Description |
|---|---|---|
| Part 1: Monotherapy Dose-escalation | EXPERIMENTAL | Oral treatment with IAM1363 capsules, administered in increasing dose levels starting at 120 mg QD in 21-day cycles. |
| Part 2: Monotherapy Dose Optimization | EXPERIMENTAL | Oral treatment with IAM1363 capsules, administered in 21-day cycles. Participants randomized to receive either 960 mg QD or 1200 mg QD. |
| Part 3: Monotherapy Dose Expansion | EXPERIMENTAL | Oral treatment with IAM1363 capsules or tablets, administered in up to 5 cohorts at 960 mg QD in 21-day cycles. |
| Part 4: Combination Cohorts | EXPERIMENTAL | Oral treatment with IAM1363 capsules or tablets, administered in combination with either capecitabine + trastuzumab (HER2+ metastatic breast cancer), capecitabine + zanidatamab (HER2+ metastatic breast cancer), T-Dxd (HER2+ gastroesophageal adenocarcinoma), and pembrolizumab +/- carboplatin +/- pemetrexed (HER2 amplified or overexpressing non-squamous NSCLC) in 14 or 21-day cycles. |
| Name | Type | Description |
|---|---|---|
| IAM1363 | DRUG | IAM1363 monotherapy |
| Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab | DRUG | Cohort 4A |
| Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab | DRUG | Cohort 4B |
| Oral treatment with IAM1363 capsules or tablets, administered in combination with T-Dxd | DRUG | Cohort 4C |
| Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed | DRUG | Cohort 4D |
Key Inclusion Criteria: * Age ≥ 18 years (or adult age per local regulations for the country) * Have relapsed/refractory HER2-altered malignancy; for selected cohorts, prospective confirmation of HER2 alteration by central testing is required * Have progression of disease after the last systemic th...